About Invitae Corporation (NYSE:NVTA)
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
Industry, Sector and Symbol
Industry Bio Diagnostics & Testing
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$25.05 million
Price / Sales18.07
Price / CashN/A
Book Value$2.37 per share
Price / Book3.61
Return on Equity-115.25%
Return on Assets-67.79%
Frequently Asked Questions for Invitae Corporation (NYSE:NVTA)
What is Invitae Corporation's stock symbol?
Invitae Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were Invitae Corporation's earnings last quarter?
Invitae Corporation (NYSE:NVTA) posted its quarterly earnings results on Monday, August, 8th. The medical research company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.76) by $0.01. The medical research company had revenue of $5.60 million for the quarter, compared to analyst estimates of $5.81 million. Invitae Corporation had a negative return on equity of 115.25% and a negative net margin of 206.95%. The business's revenue was up 211.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.76) EPS. View Invitae Corporation's Earnings History.
When will Invitae Corporation make its next earnings announcement?
Where is Invitae Corporation's stock going? Where will Invitae Corporation's stock price be in 2017?
3 equities research analysts have issued 12-month price objectives for Invitae Corporation's stock. Their predictions range from $12.00 to $16.00. On average, they anticipate Invitae Corporation's stock price to reach $14.33 in the next twelve months. View Analyst Ratings for Invitae Corporation.
Who are some of Invitae Corporation's key competitors?
Some companies that are related to Invitae Corporation include Heron Therapeutics (HRTX), Omeros Corporation (OMER), Almost Family (AFAM), Flexion Therapeutics (FLXN), Epizyme (EPZM), AxoGen (AXGN), Cellectis S.A. (CLLS), Cardiovascular Systems (CSII), Intra-Cellular Therapies (ITCI), Lantheus Holdings (LNTH), Glaukos Corporation (GKOS), K2M Group Holdings (KTWO), Retrophin (RTRX), Pharming Group NV (PHGUF), BioTelemetry (BEAT), Intellia Therapeutics (NTLA), Revance Therapeutics (RVNC) and Anika Therapeutics (ANIK).
Who are Invitae Corporation's key executives?
Invitae Corporation's management team includes the folowing people:
- Randal W. Scott Ph.D., Executive Chairman of the Board (Age 59)
- Sean E. George Ph.D., President, Chief Executive Officer, Co-Founder, Director (Age 43)
- Shelly D Guyer, Chief Financial Officer (Age 56)
- Lee Bendekgey J.D., Chief Operating Officer, General Counsel, Secretary (Age 59)
- Robert L. Nussbaum M.D., Chief Medical Officer (Age 67)
- Christine M. Gorjanc, Lead Independent Director (Age 60)
- Eric Aguiar M.D., Independent Director (Age 55)
- Geoffrey S. Crouse, Independent Director (Age 46)
When did Invitae Corporation IPO?
(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Who owns Invitae Corporation stock?
Invitae Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (3.75%), Orbimed Advisors LLC (3.02%), Bank of New York Mellon Corp (0.35%), Allianz Asset Management GmbH (0.34%), Schwab Charles Investment Management Inc. (0.32%) and Private Wealth Partners LLC (0.20%). Company insiders that own Invitae Corporation stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Lisa Alderson, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George and Thomas Brida. View Institutional Ownership Trends for Invitae Corporation.
Who sold Invitae Corporation stock? Who is selling Invitae Corporation stock?
Invitae Corporation's stock was sold by a variety of institutional investors in the last quarter, including Cubist Systematic Strategies LLC and California State Teachers Retirement System. Company insiders that have sold Invitae Corporation company stock in the last year include E Lee Bendekgey, Katherine Stueland, Patty Dumond, Robert L Nussbaum and Thomas Brida. View Insider Buying and Selling for Invitae Corporation.
Who bought Invitae Corporation stock? Who is buying Invitae Corporation stock?
Invitae Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Orbimed Advisors LLC, Private Wealth Partners LLC, Allianz Asset Management GmbH, Schwab Charles Investment Management Inc., Fox Run Management L.L.C., OxFORD Asset Management LLP and CAPROCK Group Inc.. Company insiders that have bought Invitae Corporation stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse, Randal W Scott and Sean E George. View Insider Buying and Selling for Invitae Corporation.
How do I buy Invitae Corporation stock?
Shares of Invitae Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invitae Corporation's stock price today?
One share of Invitae Corporation stock can currently be purchased for approximately $8.55.
How big of a company is Invitae Corporation?
Invitae Corporation has a market capitalization of $457.98 million and generates $25.05 million in revenue each year. The medical research company earns $-100,250,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. Invitae Corporation employs 332 workers across the globe.
How can I contact Invitae Corporation?
Invitae Corporation's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for Invitae Corporation (NVTA)MarketBeat's community ratings are surveys of what our community members think about Invitae Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History and Estimates Chart for Invitae Corporation (NYSE:NVTA)
Earnings History by Quarter for Invitae Corporation (NYSE NVTA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2017||6/30/2017||($0.64)||($0.66)||$13.31 million||$14.34 million||View||Listen|
|5/9/2017||Q1 2017||($0.68)||($0.64)||$10.90 million||$10.34 million||View||Listen|
|2/13/2017||Q416||($0.73)||($0.69)||$8.82 million||$9.20 million||View||N/A|
|11/7/2016||Q316||($0.72)||($0.77)||$7.50 million||$6.30 million||View||Listen|
|8/8/2016||Q216||($0.76)||($0.77)||$5.81 million||$5.60 million||View||N/A|
|5/9/2016||Q116||($0.76)||($0.80)||$4.38 million||$4.00 million||View||N/A|
|2/9/2016||Q415||($0.72)||($0.76)||$2.92 million||$3.20 million||View||N/A|
|11/5/2015||Q315||($0.70)||($0.71)||$2.55 million||$2.19 million||View||N/A|
|8/6/2015||Q215||($0.55)||($0.76)||$1.67 million||$1.80 million||View||N/A|
|5/12/2015||Q115||($0.51)||($1.09)||$1.07 million||$1.23 million||View||Listen|
Earnings Estimates for Invitae Corporation (NYSE:NVTA)
Current Year EPS Consensus Estimate: $-2.45 EPS
Next Year EPS Consensus Estimate: $-1.7 EPS
Dividend History for Invitae Corporation (NYSE:NVTA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Invitae Corporation (NYSE NVTA)
Insider Ownership Percentage: 9.90%
Institutional Ownership Percentage: 59.22%
Insider Trades by Quarter for Invitae Corporation (NYSE NVTA)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/10/2017||Patty Dumond||VP||Sell||2,497||$10.00||$24,970.00|| |
|10/9/2017||Patty Dumond||VP||Sell||1,882||$10.00||$18,820.00|| |
|9/12/2017||Katherine Stueland||Insider||Sell||612||$9.40||$5,752.80|| |
|2/16/2017||Thomas Brida||General Counsel||Sell||766||$9.69||$7,422.54|| |
|2/15/2017||E Lee Bendekgey||CFO||Sell||2,098||$9.59||$20,119.82|| |
|2/15/2017||Patty Dumond||VP||Sell||1,264||$9.55||$12,071.20|| |
|2/15/2017||Robert L Nussbaum||Insider||Sell||1,686||$9.53||$16,067.58|| |
|2/15/2017||Thomas Brida||General Counsel||Sell||794||$9.54||$7,574.76|| |
|11/22/2016||Randal W Scott||Chairman||Buy||66,666||$6.00||$399,996.00|| |
|11/18/2016||Geoffrey Crouse||Director||Buy||15,000||$6.25||$93,750.00|| |
|11/17/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||733,333||$6.00||$4,399,998.00|| |
|9/16/2016||Patty Dumond||VP||Sell||1,000||$8.00||$8,000.00|| |
|8/15/2016||Patty Dumond||VP||Sell||1,000||$8.81||$8,810.00|| |
|7/14/2016||Patty Dumond||VP||Sell||1,000||$8.79||$8,790.00|| |
|6/16/2016||Patty Dumond||VP||Sell||1,000||$8.00||$8,000.00|| |
|5/17/2016||Patty Dumond||VP||Sell||3,221||$8.47||$27,281.87|| |
|4/14/2016||Patty Dumond||VP||Sell||1,000||$10.50||$10,500.00|| |
|2/22/2016||Lisa Alderson||Insider||Sell||7,500||$7.64||$57,300.00|| |
|2/11/2016||Sean E George||COO||Buy||16,950||$6.16||$104,412.00|| |
|2/18/2015||James E Flynn||Insider||Buy||175,000||$16.00||$2,800,000.00|| |
Latest Headlines for Invitae Corporation (NYSE NVTA)
Invitae Corporation (NYSE NVTA) Chart for Saturday, November, 25, 2017